阿巴西普治疗复发型非严重肉芽肿性多血管炎的随机双盲安慰剂对照试验
这项多中心随机双盲安慰剂对照试验纳入65例复发型非严重肉芽肿性多血管炎(GPA)患者,比较阿巴西普125 mg每周一次皮下注射与安慰剂(均联合泼尼松30 mg/日,第12周逐渐减停)的疗效。主要终点治疗失败率在两组间无统计学差异(P=0.853),关键次要终点亦无统计学差异。结论认为阿巴西普未降低复发、严重恶化或未达到缓解的风险。
要点
- 阿巴西普组与安慰剂组治疗失败率无统计学差异(P=0.853)。
- 阿巴西普在至完全缓解时间、无糖皮质激素缓解持续时间等关键次要终点与安慰剂无统计学差异。
- 两组不良事件(包括感染)的频率或严重程度无差异。
核心结论
- 在复发型非严重GPA患者中,阿巴西普未降低复发、严重恶化或未达到缓解的风险。
研究设计与样本
- 多中心随机双盲安慰剂对照试验,65例复发型非严重GPA患者随机分为阿巴西普组34例和安慰剂组31例。
- 阿巴西普125 mg每周一次皮下注射或安慰剂,均联合泼尼松30 mg/日(或等效剂量),第12周逐渐减停。
- 已在使用甲氨蝶呤、硫唑嘌呤、吗替麦考酚酯或来氟米特的患者以稳定剂量继续用药。
主要发现
- 阿巴西普组与安慰剂组治疗失败率无统计学差异(P=0.853)。
- 阿巴西普在至完全缓解时间(BVAS/WG=0)、无糖皮质激素缓解持续时间、复发严重程度、损伤预防及患者报告生活质量等关键次要终点与安慰剂无统计学差异。
- 两组不良事件(包括感染)的频率或严重程度无差异。
关键数值与推荐
- 主要终点为治疗失败率,定义为6个月内复发、疾病恶化或未能达到BVAS/WG评分0或1。
- 达到缓解的患者维持随机分组直至复发、提前终止或末例患者入组后12个月的共同截止日期。
- 发生非严重复发、非严重恶化或至第6个月未缓解的患者可选择接受开放标签阿巴西普。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). METHODS: In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or equivalent), tapered and discontinued at week 12. Patients already taking methotrexate, azathioprine, mycophenolate, or leflunomide continued this medication at a stable dose. Patients achieving remission remained on their randomized assignment until relapse, early termination, or the common close date 12 months after enrollment of the last patient. Those who had a nonsevere relapse, had nonsevere worsening, or were not in remission by month 6 had the option to receive open-label abatacept. The primary end point was the rate of treatment failure, defined as relapse, disease worsening, or failure to achieve a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0 or 1 by six months. RESULTS: Sixty-five patients were randomized; 34 received abatacept and 31 received placebo. No statistical difference in the treatment failure rate was found between those who received abatacept and those who received placebo (P = 0.853). Treatment with abatacept did not demonstrate any statistical difference from placebo in key secondary end points, including time to full remission (BVAS/WG = 0), duration of glucocorticoid-free remission, relapse severity, prevention of damage, and patient-reported quality-of-life outcomes. There was no difference in the frequency or severity of adverse events between treatment arms, including infection. CONCLUSION: In patients with relapsing, nonsevere GPA, abatacept did not reduce the risk of relapse, severe worsening, or failure to achieve remission.
引用
- Langford CA, Khalidi N, Springer J, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis. Arthritis Rheumatol. 2025. PMID: 40506793. doi:10.1002/art.43272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。